---
document_datetime: 2025-12-02 05:36:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dectova.html
document_name: dectova.html
version: success
processing_time: 0.1019057
conversion_datetime: 2025-12-27 09:38:23.880876
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dectova

[RSS](/en/individual-human-medicine.xml/67197)

##### Authorised

This medicine is authorised for use in the European Union

zanamivir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dectova](#news-on)
- [More information on Dectova](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Dectova is an antiviral medicine used to treat complicated and potentially life-threatening influenza (flu) caused by either the influenza A or B virus in adults and children from 6 months of age. Complicated influenza is a severe flu infection that requires hospitalisation of the patient.

The medicine is used when the virus is resistant to other flu treatments or when other antiviral treatments, including inhaled zanamivir are not suitable for the patient.

Dectova contains the active substance zanamivir.

Expand section

Collapse section

## How is Dectova used?

Dectova is given as an infusion (drip) into a vein. The recommended dose for adults is 600 mg twice daily for 5 to 10 days while for children the dose is adjusted based on weight. Lower doses are given to adults and children with reduced kidney function.

Treatment is started as soon as possible and usually within 6 days after symptoms start.

Dectova can only be obtained with a prescription. For more information about using Dectova, see the package leaflet or contact your doctor or pharmacist.

## How does Dectova work?

The active substance in Dectova, zanamivir, prevents the flu virus from spreading by blocking some of the enzymes on the surface of the virus called neuraminidases. When the neuraminidases are blocked, the virus cannot spread. Dectova works on neuraminidases of both influenza A (the most common type) and influenza B viruses.

## What benefits of Dectova have been shown in studies?

Dectova has been shown to work as well as Tamiflu (the standard of care for complicated flu) in one main study involving 626 patients who had been hospitalised. The main measure of effectiveness was how long it took for patients to leave hospital or for 4 out of the following 5 flu symptoms to resolve: fever, decreased levels of oxygen in the blood, raised breathing rate, raised heart rate and abnormal blood pressure. It took around 5.1 days for symptoms to resolve or patients to leave the hospital with Dectova compared with 5.6 days with Tamiflu.

Although Tamiflu was used as the comparator, there is some uncertainty about how effective this medicine is in complicated influenza as it has not been compared with placebo (a dummy treatment) in hospitalised influenza patients.

Further evidence on benefits of Dectova comes from supporting clinical studies and other laboratory studies.

## What are the risks associated with Dectova?

The most common side effects with Dectova (which may affect up to 1 in 10 people) are diarrhoea, raised levels of transaminases (liver enzymes), liver injury and rash. The most serious side effect is liver injury.

For the full list of side effects and restrictions, see the package leaflet.

## Why is Dectova authorised in the EU?

A main study showed that Dectova works as well as Tamiflu, with comparable time to discharge patients from hospital or resolution of most of the influenza symptoms. Evidence from laboratory and other clinical studies also supported the effectiveness of Dectova.

Dectova is expected to be effective against some flu strains that do not respond to other flu treatments. Its side effects, the most important one being liver injury, are similar to those seen with Tamiflu.

The European Medicines Agency therefore decided that Dectova's benefits are greater than its risks and it can be authorised for use in the EU.

However, because uncertainties remain about the size of the effect of Tamiflu (and by extension the size of Dectova's effect), Dectova has been authorised under 'exceptional circumstances'. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Dectova?

Since Dectova has been authorised under exceptional circumstances, the company that markets the medicine will conduct two observational studies in patients with complicated influenza to obtain further data on the effectiveness.

## What measures are being taken to ensure the safe and effective use of Dectova?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dectova have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dectova are continuously monitored. Side effects reported with Dectova are carefully evaluated and any necessary action taken to protect patients.

## Other information about Dectova

Dectova received a marketing authorisation valid throughout the EU on 26 April 2019.

Dectova : EPAR - Medicine overview

Reference Number: EMA/161401/2019

English (EN) (77.69 KB - PDF)

**First published:** 07/06/2019

[View](/en/documents/overview/dectova-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-520)

български (BG) (101 KB - PDF)

**First published:**

07/06/2019

[View](/bg/documents/overview/dectova-epar-medicine-overview_bg.pdf)

español (ES) (75.08 KB - PDF)

**First published:**

07/06/2019

[View](/es/documents/overview/dectova-epar-medicine-overview_es.pdf)

čeština (CS) (97.64 KB - PDF)

**First published:**

07/06/2019

[View](/cs/documents/overview/dectova-epar-medicine-overview_cs.pdf)

dansk (DA) (74.46 KB - PDF)

**First published:**

07/06/2019

[View](/da/documents/overview/dectova-epar-medicine-overview_da.pdf)

Deutsch (DE) (76.26 KB - PDF)

**First published:**

07/06/2019

[View](/de/documents/overview/dectova-epar-medicine-overview_de.pdf)

eesti keel (ET) (73.46 KB - PDF)

**First published:**

07/06/2019

[View](/et/documents/overview/dectova-epar-medicine-overview_et.pdf)

ελληνικά (EL) (107.71 KB - PDF)

**First published:**

07/06/2019

[View](/el/documents/overview/dectova-epar-medicine-overview_el.pdf)

français (FR) (75.97 KB - PDF)

**First published:**

07/06/2019

[View](/fr/documents/overview/dectova-epar-medicine-overview_fr.pdf)

hrvatski (HR) (94.85 KB - PDF)

**First published:**

07/06/2019

[View](/hr/documents/overview/dectova-epar-medicine-overview_hr.pdf)

italiano (IT) (74.55 KB - PDF)

**First published:**

07/06/2019

[View](/it/documents/overview/dectova-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (102.54 KB - PDF)

**First published:**

07/06/2019

[View](/lv/documents/overview/dectova-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (96.68 KB - PDF)

**First published:**

07/06/2019

[View](/lt/documents/overview/dectova-epar-medicine-overview_lt.pdf)

magyar (HU) (94.19 KB - PDF)

**First published:**

07/06/2019

[View](/hu/documents/overview/dectova-epar-medicine-overview_hu.pdf)

Malti (MT) (104.87 KB - PDF)

**First published:**

07/06/2019

[View](/mt/documents/overview/dectova-epar-medicine-overview_mt.pdf)

Nederlands (NL) (74.86 KB - PDF)

**First published:**

07/06/2019

[View](/nl/documents/overview/dectova-epar-medicine-overview_nl.pdf)

polski (PL) (98.86 KB - PDF)

**First published:**

07/06/2019

[View](/pl/documents/overview/dectova-epar-medicine-overview_pl.pdf)

português (PT) (75.18 KB - PDF)

**First published:**

07/06/2019

[View](/pt/documents/overview/dectova-epar-medicine-overview_pt.pdf)

română (RO) (96.96 KB - PDF)

**First published:**

07/06/2019

[View](/ro/documents/overview/dectova-epar-medicine-overview_ro.pdf)

slovenčina (SK) (97.68 KB - PDF)

**First published:**

07/06/2019

[View](/sk/documents/overview/dectova-epar-medicine-overview_sk.pdf)

slovenščina (SL) (93.71 KB - PDF)

**First published:**

07/06/2019

[View](/sl/documents/overview/dectova-epar-medicine-overview_sl.pdf)

Suomi (FI) (74.45 KB - PDF)

**First published:**

07/06/2019

[View](/fi/documents/overview/dectova-epar-medicine-overview_fi.pdf)

svenska (SV) (74.84 KB - PDF)

**First published:**

07/06/2019

[View](/sv/documents/overview/dectova-epar-medicine-overview_sv.pdf)

Dectova : EPAR - Risk management plan

English (EN) (1.46 MB - PDF)

**First published:** 11/12/2024

[View](/en/documents/rmp/dectova-epar-risk-management-plan_en.pdf)

## Product information

Dectova : EPAR - Product information

English (EN) (414.59 KB - PDF)

**First published:** 07/06/2019

**Last updated:** 10/11/2025

[View](/en/documents/product-information/dectova-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-404)

български (BG) (487.13 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/bg/documents/product-information/dectova-epar-product-information_bg.pdf)

español (ES) (447.82 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/es/documents/product-information/dectova-epar-product-information_es.pdf)

čeština (CS) (438.67 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/cs/documents/product-information/dectova-epar-product-information_cs.pdf)

dansk (DA) (406.61 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/da/documents/product-information/dectova-epar-product-information_da.pdf)

Deutsch (DE) (403.71 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/de/documents/product-information/dectova-epar-product-information_de.pdf)

eesti keel (ET) (528.34 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/et/documents/product-information/dectova-epar-product-information_et.pdf)

ελληνικά (EL) (425.57 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/el/documents/product-information/dectova-epar-product-information_el.pdf)

français (FR) (428.9 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/fr/documents/product-information/dectova-epar-product-information_fr.pdf)

hrvatski (HR) (401.53 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/hr/documents/product-information/dectova-epar-product-information_hr.pdf)

íslenska (IS) (373.55 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/is/documents/product-information/dectova-epar-product-information_is.pdf)

italiano (IT) (498.3 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/it/documents/product-information/dectova-epar-product-information_it.pdf)

latviešu valoda (LV) (486.43 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/lv/documents/product-information/dectova-epar-product-information_lv.pdf)

lietuvių kalba (LT) (459.11 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/lt/documents/product-information/dectova-epar-product-information_lt.pdf)

magyar (HU) (492.45 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/hu/documents/product-information/dectova-epar-product-information_hu.pdf)

Malti (MT) (491.81 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/mt/documents/product-information/dectova-epar-product-information_mt.pdf)

Nederlands (NL) (467.17 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/nl/documents/product-information/dectova-epar-product-information_nl.pdf)

norsk (NO) (393.68 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/no/documents/product-information/dectova-epar-product-information_no.pdf)

polski (PL) (525.35 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/pl/documents/product-information/dectova-epar-product-information_pl.pdf)

português (PT) (442.16 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/pt/documents/product-information/dectova-epar-product-information_pt.pdf)

română (RO) (510.6 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/ro/documents/product-information/dectova-epar-product-information_ro.pdf)

slovenčina (SK) (403.09 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/sk/documents/product-information/dectova-epar-product-information_sk.pdf)

slovenščina (SL) (438.9 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/sl/documents/product-information/dectova-epar-product-information_sl.pdf)

Suomi (FI) (408.42 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/fi/documents/product-information/dectova-epar-product-information_fi.pdf)

svenska (SV) (408.73 KB - PDF)

**First published:**

07/06/2019

**Last updated:**

10/11/2025

[View](/sv/documents/product-information/dectova-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000308615 10/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dectova : EPAR - All authorised presentations

English (EN) (32.81 KB - PDF)

**First published:** 07/06/2019

[View](/en/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-838)

български (BG) (49.03 KB - PDF)

**First published:**

07/06/2019

[View](/bg/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_bg.pdf)

español (ES) (51.74 KB - PDF)

**First published:**

07/06/2019

[View](/es/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29.82 KB - PDF)

**First published:**

07/06/2019

[View](/cs/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (7.01 KB - PDF)

**First published:**

07/06/2019

[View](/da/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (10.48 KB - PDF)

**First published:**

07/06/2019

[View](/de/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (7.34 KB - PDF)

**First published:**

07/06/2019

[View](/et/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (49.23 KB - PDF)

**First published:**

07/06/2019

[View](/el/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_el.pdf)

français (FR) (15.51 KB - PDF)

**First published:**

07/06/2019

[View](/fr/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25 KB - PDF)

**First published:**

07/06/2019

[View](/hr/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (87.95 KB - PDF)

**First published:**

07/06/2019

[View](/is/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_is.pdf)

italiano (IT) (11.52 KB - PDF)

**First published:**

07/06/2019

[View](/it/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (27.94 KB - PDF)

**First published:**

07/06/2019

[View](/lv/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (46.98 KB - PDF)

**First published:**

07/06/2019

[View](/lt/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (93.72 KB - PDF)

**First published:**

07/06/2019

[View](/hu/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (26.81 KB - PDF)

**First published:**

07/06/2019

[View](/mt/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (11.9 KB - PDF)

**First published:**

07/06/2019

[View](/nl/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (59.71 KB - PDF)

**First published:**

07/06/2019

[View](/no/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_no.pdf)

polski (PL) (47.99 KB - PDF)

**First published:**

07/06/2019

[View](/pl/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_pl.pdf)

português (PT) (10.85 KB - PDF)

**First published:**

07/06/2019

[View](/pt/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_pt.pdf)

română (RO) (47.26 KB - PDF)

**First published:**

07/06/2019

[View](/ro/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.46 KB - PDF)

**First published:**

07/06/2019

[View](/sk/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.87 KB - PDF)

**First published:**

07/06/2019

[View](/sl/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (66.1 KB - PDF)

**First published:**

07/06/2019

[View](/fi/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.96 KB - PDF)

**First published:**

07/06/2019

[View](/sv/documents/all-authorised-presentations/dectova-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dectova Active substance zanamivir International non-proprietary name (INN) or common name zanamivir Therapeutic area (MeSH) Influenza, Human Anatomical therapeutic chemical (ATC) code J05AH01

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when:

- The patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or
- Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.

Dectova should be used in accordance with official guidance.

## Authorisation details

EMA product number EMEA/H/C/004102

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk Citywest Business Campus Dublin 24 D24 YK11 Ireland

Opinion adopted 26/04/2019 Marketing authorisation issued 26/04/2019 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dectova : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (145.38 KB - PDF)

**First published:** 11/09/2025

**Last updated:** 10/11/2025

[View](/en/documents/procedural-steps-after/dectova-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Dectova : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (162.31 KB - PDF)

**First published:** 16/10/2019

**Last updated:** 11/09/2025

[View](/en/documents/procedural-steps-after/dectova-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Dectova : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/851480/2018

English (EN) (2.32 MB - PDF)

**First published:** 07/06/2019

[View](/en/documents/assessment-report/dectova-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Dectova

Adopted

Reference Number: EMA/CHMP/851518/2018

English (EN) (101.11 KB - PDF)

**First published:** 01/03/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dectova_en.pdf)

#### News on Dectova

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019) 01/03/2019

#### More information on Dectova

- [A retrospective observational chart review study to evaluate the clinical effectiveness of treatment with zanamivir 10 mg/ml solution for infusion in a cohort of intensive care unit-treated (ICU) patients with complicated influenza infection (208165) - post-authorisation study](https://catalogues.ema.europa.eu/study/48211)
- [Zanamivir 10mg/ml solution for infusion pregnancy registry: an observational study of the safety of zanamivir 10mg/ml solution for infusion exposure in pregnant women with complicated influenza and their offspring (208140) - post-authorisation study](https://catalogues.ema.europa.eu/study/49381)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 10/11/2025

## Share this page

[Back to top](#main-content)